This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
hospital in Vienna, Austria. Thirty patients were allocated to each group.
Study design
The study type was a prospective randomised, double-blind, controlled trial (RCT). Consecutive patients were randomly allocated to one of the two NMBas being tested. The patients and all operating staff, apart from the nurse assigned to prepare the NMBa, were blinded to the type of NMBa used. Follow-up was to the point of leaving the operating theatre. There was no loss to follow-up. Adverse events were recorded by the anaesthesiologists, anaesthesia nurses, postanaesthesia care unit nurses or ward nurses, all of whom were blinded to the type of NMBa used.
Analysis of effectiveness
Analysis of effectiveness was based on intention to treat.
The primary health outcomes used in the analysis were: duration of suppression of TI (using relaxometer mechanomyograph); haemodynamic stability following administration of NMBa; and incidence of erythema.
There were no significant differences between the groups in age, height or weight. No adjustments were made for known confounding factors. Randomisation was employed to account for unknown confounding factors.
Effectiveness results
None of the demographic data, anaesthetic requirements or duration of anaesthesia or surgery reached statistical significance, with the exception of those shown below.
Recovery time (minutes): mivacurium = 8.1, rocuronium = 14.1, (p=0.005).
Pharmacodynamic results following initial dose: all the results reached statistical significance, a selection are reported below.
Start NMBa to 25% TI recovery (minutes): mivacurium = 19.9 (SD=4.4), rocuronium = 25.8 (SD=6.5), (p<0.001); TI recovery 25% to 75% (minutes): mivacurium = 6.7 (SD=2.3), rocuronium = 11.9 (SD=3.9), (p<0.001); and complete recovery time (minutes): mivacurium = 39.2 (SD=8.1), rocuronium = 52.6 (SD=15.5), (p=0.033).
Pharmacodynamic results following last maintenance dose: all the results reached statistical significance, a selection are reported below.
dose:
TI recovery 25% to 75% (minutes): mivacurium = 6.8, rocuronium = 12,5.
doses:
TI recovery 25% to 75% (minutes): mivacurium = 5.6, rocuronium = 16.0.
Systolic arterial pressure and diastolic arterial pressure following NMBa dose: mivacurium: decline; rocuronium: no change.
Number of patients with maintenance doses: mivacurium = 22, rocuronium = 14.
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Number manifesting erythema: mivacurium = 13, rocuronium = 0.
Clinical conclusions
For laparoscopic gynaecological surgery, equi-lasting doses of rocuronium resulted in favourable intubating conditions more rapidly, improved haemodynamic stability, required less frequent administration of maintenance doses and were not associated with erythema, compared to mivacurium.
Measure of benefits used in the economic analysis
No summary measure of benefit was derived and, as such, a cost-consequences analysis was conducted.
Direct costs
Discounting was not relevant as the duration of the study was less than one day. Quantities were assessed for those variables that had different cost implications for the two groups. These were: the number of ampules of the NMBa actually used for the two groups, and time from end of surgery to extubation. Costs were estimated using commercial prices. Quantities and prices relate to 2001.
Statistical analysis of costs
Costs were not treated stochastically.
Indirect Costs
Indirect costs were not estimated, although the authors did make some calculations based on the hospital costs of running an operating room and referred to them as indirect costs. However, these are not indirect costs.
Currency
Euros (Euro).
Sensitivity analysis
No sensitivity analysis was conducted
Estimated benefits used in the economic analysis
See effectiveness results reported earlier.
Cost results
The cost results were as follows:
NMBa cost/patient: mivacurium = Euro 6.93, rocuronium = Euro 8.96.
Incremental cost/patient in rocuronium group for 6 minute extra recovery time = Euro 45.
Synthesis of costs and benefits
Not relevant.
Authors' conclusions
For laparoscopic gynaecological surgery, equi-lasting doses of rocuronium resulted in favourable intubating conditions
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CRD COMMENTARY -Selection of comparators
Two NMBas were compared: mivacurium and rocuronium. The selection of the two for comparison was justified on the grounds that they were commonly used for the type of surgery considered. You, as a user of this database, should decide if they represent valid comparators in your own setting.
Validity of estimate of measure of effectiveness
The analysis was based on a double-blinded RCT, which was appropriate for the study question. The method of randomisation was reported and the study sample was representative of the study population. Due to these facts the overall internal validity of the study was likely to be quite high. Patient groups were shown to be comparable at analysis; additionally this contributes to the internal validity of the study. The statistical analysis was appropriate. Power calculations were conducted. However it should be noted that the power calculations were based on estimates of differences in TI recovery times and so the internal validity of the various measures of benefit may be reduced.
Validity of estimate of measure of benefit
No summary measure of benefit was used. Benefits were assessed in terms of intubating conditions, haemodynamic stability, number of maintenance doses needed and incidence of erythema.
Validity of estimate of costs
The only costs included in the analysis were costs of ampules of NMBA and theatre time. These were valid as they were the only costs that varied between the two groups. Quantities were reported separately from costs for both the number of ampules needed and the additional theatre time. No price year was reported, thus hindering any reflation exercise. Discounting was not appropriate due to the short time scale, and therefore was not conducted. Uncertainty in the cost results was not investigated. The reproducibility of the results obtained is limited.
Other issues
Comparisons of duration 25% under balanced anaesthesia of the two NMBas were made with two other studies with very limited observations and are therefore difficult to interpret. Patients were allowed to recover spontaneously from the NMBa. However, this may not always be feasible in the clinical setting, where reversal of the NMBa may be necessary, due to lack of sensitive neuromuscular monitoring facilities. This would influence the costs in two ways, viz: increased cost of drugs, and reduced cost of theatre time. Thus the generalisability of the results is questionable.
